Drug Trial News

RSS

Scientists identify new drugs that have potential to slow down progression of Parkinson's

New drugs which may have the potential to stop faulty brain cells dying and slow down the progression of Parkinson's, have been identified by scientists in a pioneering study which is the first of its kind.

4 Sep 2013

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or "bad cholesterol").

4 Sep 2013

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467.

3 Sep 2013

Prana's PBT2 drug recognised as one of the most promising treatments under development

Prana Biotechnology, a leading global developer of first-in-class treatments for neurodegenerative disease, is pleased to announce Elsevier Business Intelligence has named clinical drug PBT2 as one of the Top 10 Neuroscience Projects to Watch.

3 Sep 2013

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

3 Sep 2013

Omecamtiv mecarbil fails to achieve primary endpoint in phase II ATOMIC-AHF study

Omecamtiv mecarbil, a cardiac myosin-activator, did not achieve its primary efficacy endpoint in reducing dyspnoea (shortness of breath) in patients with acute heart failure, according to the results of the phase II ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) study.

3 Sep 2013

Acacia Pharma raises $23.5 million in Series B financing

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised £15 million (~$23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S.

3 Sep 2013

Anti-diabetic drug alogliptin meets primary endpoint in EXAMINE trial

Patients with type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo according to results of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial presented at the European Society of Cardiology Congress.

2 Sep 2013

Debiopharm starts Debio 1347 phase I study in patients with advanced solid tumors

Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.

2 Sep 2013

Ipsen announces results of phase III study of somatuline in patients with neuroendocrine tumors

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the detailed results of phase III CLARINET study assessing the effect of Somatuline® Autogel® 120 mg in patients with gastrointestinal and pancreatic neuroendocrine tumors ("GEP-NETs")1 will be disclosed for the first time on September 28, 2013 at the European Cancer Congress 2013 (Sept. 27 - Oct. 1, 2013) in Amsterdam.

31 Aug 2013

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

Dezima Pharma, the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the initiation of a double blind, placebo controlled, Phase 2b dose ranging study of DEZ-001 (previously TA-8995), alone and in combination with statins, in order to study the effects on a wide range of lipids and other biomarkers of cardiovascular disease in patients with mild dyslipidemia.

30 Aug 2013

Mallinckrodt to present MNK-795 clinical data at PAINWeek 2013

Mallinckrodt announced today that the first clinical data on MNK-795 will be presented at PAINWeek 2013, to be held September 4-7 in Las Vegas. MNK-795 is an extended-release oral formulation of oxycodone and acetaminophen that has been studied in clinical trials for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.

29 Aug 2013

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

OxyContin contains oxycodone, which is an opioid agonist. It is used for the management of moderate to severe pain when a constant opioid analgesic is needed for a prolonged period of time.

29 Aug 2013

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Approval for the IMAGINE trial was granted by the Austin Health Research Ethics Committee in November 2011, with the first patients dosed in March the following year. However, well before the trial was approved, PBT2 had already shown promise in significantly changing Abeta levels in spinal fluid while improving cognition in a previous 12-week trial conducted in 2006.

28 Aug 2013

Results from Phase II START study published in The Lancet Diabetes & Endocrinology

Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) and sponsored by the Immune Tolerance Network, are published today in The Lancet Diabetes & Endocrinology.

28 Aug 2013

Clinical trial to study benefits of statins in prevention of heart attacks and strokes

Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll Professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University, recently published a commentary in the American Journal of Medicine, about the benefits of statins in the prevention of heart attacks and strokes in subjects previously thought at too low a risk to be treated.

28 Aug 2013

HCV treatment with sofosbuvir and ribavirin results in sustained virologic response

Treatment of chronic hepatitis C virus genotype 1 infection with the interferon-free regimen of sofosbuvir and ribavirin resulted in a high sustained virologic response rate in a patient population with unfavorable treatment characteristics, according to a study in the August 28 issue of JAMA.

28 Aug 2013

Virttu Biologics treats first cohort of patients in SEPREHVIR Phase I/IIa study

Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced that it has treated the first cohort of patients in its Phase I/IIa clinical study of its oncolytic virus, SEPREHVIR (HSV1716) for the treatment of malignant pleural mesothelioma.

27 Aug 2013

Lipidor announces positive results from Phase I/IIa study of AKVANO/calcipotriol for psoriasis vulgaris

Today Lipidor announced positive results from a Phase I/IIa study investigating the efficacy and tolerability of its AKVANO/calcipotriol spray formulation for the treatment of psoriasis vulgaris, the most common form of psoriasis.

27 Aug 2013

Sanofi Pasteur reports clinical benefit of Fluzone High-Dose vaccine in preventing influenza

Sanofi Pasteur, the vaccines division of Sanofi, today announced topline results of a large-scale, multi-center efficacy trial in people 65 years of age and older showing a superior clinical benefit of Fluzone High-Dose (Influenza Virus Vaccine) relative to the standard dose of Fluzone vaccine in preventing influenza.

26 Aug 2013

Drug Trial News

Scientists identify new drugs that have potential to slow down progression of Parkinson's

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Prana's PBT2 drug recognised as one of the most promising treatments under development

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Omecamtiv mecarbil fails to achieve primary endpoint in phase II ATOMIC-AHF study

Acacia Pharma raises $23.5 million in Series B financing

Anti-diabetic drug alogliptin meets primary endpoint in EXAMINE trial

Debiopharm starts Debio 1347 phase I study in patients with advanced solid tumors

Ipsen announces results of phase III study of somatuline in patients with neuroendocrine tumors

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

Mallinckrodt to present MNK-795 clinical data at PAINWeek 2013

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Results from Phase II START study published in The Lancet Diabetes & Endocrinology

Clinical trial to study benefits of statins in prevention of heart attacks and strokes

HCV treatment with sofosbuvir and ribavirin results in sustained virologic response

Virttu Biologics treats first cohort of patients in SEPREHVIR Phase I/IIa study

Lipidor announces positive results from Phase I/IIa study of AKVANO/calcipotriol for psoriasis vulgaris

Sanofi Pasteur reports clinical benefit of Fluzone High-Dose vaccine in preventing influenza

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News